Pure Global Cannabis Inc. announced that its wholly-owned subsidiary, PureSinse Inc. (PureSinse), has received approval for an amendment to its licence from Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR), to include the activity of possession of cannabis oil, resin, and relevant activities. PureSinse's license under the ACMPR was amended August 24, 2018, allowing the company to source bulk psychoactive and non-psychoactive cannabis oils along with resins from national and international licensed producers that meet Pure Global's high quality standards. The next step will be to receive Health Canada approvals to process, package, and sell cannabis oil-based products. The company anticipates that PureSinse will be granted a cannabis oils production and processing licence by the end of 2018 and subsequent oils sales licence in early 2019. Upon final licensing approval, PureSinse will have the ability to sell cannabis oil products to registered patients under the ACMPR, for adult legal use under the Cannabis Act, and for export purposes, along with its current dried medical cannabis products.